Cytosorbents (CTSO) Misses Q2 EPS by 3c
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Cytosorbents (NASDAQ: CTSO) reported Q2 EPS of ($0.12), $0.03 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.18 million.
For earnings history and earnings-related data on Cytosorbents (CTSO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Oaktree Capital Group (OAK) Posts Mixed Q3 Results
- Iradimed Corp. (IRMD) Tops Q3 EPS by 3c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!